Diethyl Oxalacetate | CAS:108-56-5

We serve Diethyl Oxalacetate CAS:108-56-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Diethyl Oxalacetate

CAS No: 108-56-5
Product Name: Diethyl Oxalacetate
Other Name:
Diethyl Oxalacetate
Diethyl 2-oxosuccinate
 
Density: 1.2±0.1 g/cm3
Boiling Point: 285.2±40.0 °C at 760 mmHg
Melting Point: 41ºC
Molecular Formula: C8H12O5
Molecular Weight: 188.178
Flash Point: 110.1±20.8 °C
Exact Mass: 188.068466
PSA: 72.83000
LogP: 0.66
Vapour Pressure: 0.0±1.3 mmHg at 25°C
Index of Refraction: 1.469
Storage condition: Freezer
 
Specification
Appearance: Colorless liquid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Imazethapyr CAS: 81335-77-5.
Be used as pesticide intermediate. Diethyl oxaloacetate is an intermediate of the herbicide imidazolenicotinic acid. Organic synthesis intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like Diethyl Oxalacetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Diethyl 2-oxosuccinate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Diethyl Oxalacetate Use and application,Diethyl 2-oxosuccinate technical grade,usp/ep/jp grade.


Related News: With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near1-butyl-4-(4-iodophenyl)benzene manufacturer GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.”2-Chloro-5-iodopyridine supplier GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.”Methyl 2-amino-4,5-dimethoxybenzoate vendor Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.